翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第五项适应症获国家药品监督管理局签发药品注册证书

Core Viewpoint - Hansoh Pharmaceutical (03692) has received a drug registration certificate from the National Medical Products Administration (NMPA) for its innovative drug Amelot (Ametinib Mesylate Tablets), approving its fifth indication for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The new indication allows Amelot to be used in combination with pemetrexed and platinum-based chemotherapy for patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [1]